MA35601B1 - Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 - Google Patents

Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1

Info

Publication number
MA35601B1
MA35601B1 MA36620A MA36620A MA35601B1 MA 35601 B1 MA35601 B1 MA 35601B1 MA 36620 A MA36620 A MA 36620A MA 36620 A MA36620 A MA 36620A MA 35601 B1 MA35601 B1 MA 35601B1
Authority
MA
Morocco
Prior art keywords
hydroxymethyl substituted
compounds
pyrrolotriazines
alk1 inhibitors
alk1
Prior art date
Application number
MA36620A
Other languages
English (en)
Inventor
Jurgen Klar
Verena Voehringer
Joachim Telser
Mario Lobell
Frank Submeier
Volkhart Min-Jian Li
Michael Bottger
Stefan Golz
Dieter Lang
Karl-Heinz Schlemmer
Thomas Schlange
Andreas Schall
Wenlang Fu
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47436537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35601(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA35601B1 publication Critical patent/MA35601B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Cette invention porte sur de nouvelles pyrrolo[2,1-f][1,2,4]triazin-4-amines 5-substituées par (hydroxyméthyl)aryle représentées par la formule (i), sur des procédés pour la préparation de tels composés, sur des compositions pharmaceutiques contenant de tels composés et sur l'utilisation de tels composés ou de telles compositions pour le traitement de troubles liés à l'angiogenèse, en particulier de troubles oculaires liés à l'angiogenèse.
MA36620A 2012-03-27 2013-12-27 Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 MA35601B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12161547 2012-03-27
PCT/EP2012/062366 WO2013004551A1 (fr) 2011-07-01 2012-06-26 Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1

Publications (1)

Publication Number Publication Date
MA35601B1 true MA35601B1 (fr) 2014-11-01

Family

ID=47436537

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36620A MA35601B1 (fr) 2012-03-27 2013-12-27 Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1

Country Status (24)

Country Link
US (1) US9040691B2 (fr)
EP (1) EP2726482B1 (fr)
JP (1) JP5955953B2 (fr)
KR (1) KR20140036269A (fr)
CN (1) CN103764657B (fr)
AP (1) AP3529A (fr)
AR (1) AR087017A1 (fr)
AU (1) AU2012280508A1 (fr)
BR (1) BR112014000049A2 (fr)
CA (1) CA2840518A1 (fr)
CO (1) CO6870031A2 (fr)
CU (1) CU20130170A7 (fr)
DO (1) DOP2013000300A (fr)
EA (1) EA023775B1 (fr)
EC (1) ECSP13013120A (fr)
ES (1) ES2598027T3 (fr)
GT (1) GT201300313A (fr)
IL (1) IL229533A0 (fr)
MA (1) MA35601B1 (fr)
MX (1) MX2013014315A (fr)
PE (1) PE20140570A1 (fr)
SG (1) SG195100A1 (fr)
UY (1) UY34167A (fr)
WO (1) WO2013004551A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
NO3175985T3 (fr) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
JP5985658B2 (ja) * 2012-01-31 2016-09-06 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． ブルトンチロシンキナーゼ阻害薬としての環状分子
WO2015157644A1 (fr) * 2014-04-10 2015-10-15 Lankenau Institute For Medical Research Méthodes et compositions pour le traitement de maladies et de troubles oculaires
EP3148993B1 (fr) 2014-05-28 2019-02-27 Bayer CropScience Aktiengesellschaft Procédé de préparation de dérivés de thiazole
US10214537B2 (en) 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
EP3209665B1 (fr) * 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Composés pyrrolotriaziniques aminés substitués en tant qu'inhibiteurs de pi3k
TW201632520A (zh) 2014-11-25 2016-09-16 拜耳製藥股份有限公司 經取代之吡啶並苯並二氮呯酮衍生物及其用途
AU2016249537B2 (en) 2015-04-16 2020-01-30 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives
WO2017035366A1 (fr) 2015-08-26 2017-03-02 Incyte Corporation Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
KR102558066B1 (ko) * 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
CN109111447A (zh) 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
KR20200088308A (ko) 2017-09-27 2020-07-22 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
MA53010A (fr) 2018-06-29 2021-05-05 Incyte Corp Formulations d'un inhibiteur de axl/mer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2328269T3 (es) * 1999-05-21 2009-11-11 Bristol-Myers Squibb Company Pirrolotriazinas como inhibires de quinasas.
AU2003254847B2 (en) 2002-08-08 2009-06-04 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US8431695B2 (en) * 2005-11-02 2013-04-30 Bayer Intellectual Property Gmbh Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CN101466710B (zh) 2005-12-02 2013-05-29 拜尔健康护理有限责任公司 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物
ES2545907T3 (es) 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
EP1873157A1 (fr) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines et sels de ceux-ci, compositions pharmaceutiques contenant ces composes, procedes de preparation associes, et leur utilisation
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
ATE522249T1 (de) * 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
ES2393430T3 (es) * 2007-10-17 2012-12-21 Novartis Ag Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK
US8507488B2 (en) * 2008-05-13 2013-08-13 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物

Also Published As

Publication number Publication date
AR087017A1 (es) 2014-02-05
CN103764657B (zh) 2016-05-25
MX2013014315A (es) 2014-01-31
AP2014007378A0 (en) 2014-01-31
CN103764657A (zh) 2014-04-30
PE20140570A1 (es) 2014-04-28
CO6870031A2 (es) 2014-02-20
US9040691B2 (en) 2015-05-26
AU2012280508A1 (en) 2013-12-12
ECSP13013120A (es) 2014-02-28
EA023775B1 (ru) 2016-07-29
UY34167A (es) 2013-01-31
CU20130170A7 (es) 2014-04-24
SG195100A1 (en) 2013-12-30
ES2598027T3 (es) 2017-01-24
DOP2013000300A (es) 2014-02-28
GT201300313A (es) 2014-11-13
NZ619453A (en) 2016-01-29
EA201490103A1 (ru) 2014-06-30
IL229533A0 (en) 2014-01-30
JP5955953B2 (ja) 2016-07-20
AP3529A (en) 2016-01-11
WO2013004551A1 (fr) 2013-01-10
US20140256718A1 (en) 2014-09-11
EP2726482B1 (fr) 2016-07-20
EP2726482A1 (fr) 2014-05-07
JP2014525902A (ja) 2014-10-02
CU24146B1 (fr) 2016-02-29
KR20140036269A (ko) 2014-03-25
CA2840518A1 (fr) 2013-01-10
BR112014000049A2 (pt) 2017-02-07

Similar Documents

Publication Publication Date Title
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA32965B1 (fr) Derives de sulfonamides
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA40893B1 (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA46038B1 (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA37439A1 (fr) Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1).
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA34308B1 (fr) Triazolopyridines substituées
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
MA49127B1 (fr) Dérivés d'indole n-substitués
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines